Abstract
Ezogabine (EZG)/retigabine (RTG) and its metabolites are mainly eliminated renally. This Phase 1 study assessed the effect of hemodialysis on the pharmacokinetics of EZG/RTG and its N-acetyl metabolite (NAMR) in patients with end-stage renal disease; tolerability of EZG/RTG was a secondary endpoint. Patients (N=8) received EZG/RTG 100 mg orally 4 hours before (Period 1) or following (Period 2) dialysis. Blood (both periods) and dialysate (Period 1) samples were taken up to 68 hours post dose. Tolerability was assessed throughout both periods. The area under the concentration– time curve (0–68 hours) for EZG/RTG was 33% lower (geometric mean ratio [90% confidence interval]: 0.67 [0.61, 0.73]) on dialysis versus off dialysis and 43% lower for NAMR (0.57 [0.53, 0.62]). Median (range) reductions in plasma concentrations from dialysis start to end were 52% (17–59%) for EZG/RTG and 51% (27–72%) for NAMR. EZG/RTG 100 mg was generally tolerated.
Keywords: End-stage renal disease, ezogabine, hemodialysis, pharmacokinetics, retigabine, tolerability.
Current Clinical Pharmacology
Title:Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease
Volume: 9 Issue: 4
Author(s): Debra J. Tompson, Mauro Buraglio, Jonathan Bullman, Christopher S. Crean and Kirsty Rayner
Affiliation:
Keywords: End-stage renal disease, ezogabine, hemodialysis, pharmacokinetics, retigabine, tolerability.
Abstract: Ezogabine (EZG)/retigabine (RTG) and its metabolites are mainly eliminated renally. This Phase 1 study assessed the effect of hemodialysis on the pharmacokinetics of EZG/RTG and its N-acetyl metabolite (NAMR) in patients with end-stage renal disease; tolerability of EZG/RTG was a secondary endpoint. Patients (N=8) received EZG/RTG 100 mg orally 4 hours before (Period 1) or following (Period 2) dialysis. Blood (both periods) and dialysate (Period 1) samples were taken up to 68 hours post dose. Tolerability was assessed throughout both periods. The area under the concentration– time curve (0–68 hours) for EZG/RTG was 33% lower (geometric mean ratio [90% confidence interval]: 0.67 [0.61, 0.73]) on dialysis versus off dialysis and 43% lower for NAMR (0.57 [0.53, 0.62]). Median (range) reductions in plasma concentrations from dialysis start to end were 52% (17–59%) for EZG/RTG and 51% (27–72%) for NAMR. EZG/RTG 100 mg was generally tolerated.
Export Options
About this article
Cite this article as:
J. Tompson Debra, Buraglio Mauro, Bullman Jonathan, S. Crean Christopher and Rayner Kirsty, Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease, Current Clinical Pharmacology 2014; 9 (4) . https://dx.doi.org/10.2174/157488470904141105142635
DOI https://dx.doi.org/10.2174/157488470904141105142635 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
New Drug Discovery from Medicinal Plants and Phytoconstituents for Depressive Disorders
CNS & Neurological Disorders - Drug Targets Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?
Medicinal Chemistry Fish Oil Prevents Oxidative Stress and Exerts Sustained Antiamnesic Effect After Global Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Cerebral Vasospasm: Practical Review of Diagnosis and Management
Reviews on Recent Clinical Trials Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Adverse Reactions to Iodinated Contrast Media Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Inflammation & Allergy - Drug Targets (Discontinued) Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Chemical and Biological Aspects of the Genus Verbesina
The Natural Products Journal Editorial (Thematic Issue: New Horizon in the Treatment of Hypertension - Role for Ca Channel Blockers - Why do Ca Channel Blockers be Focused on?)
Current Hypertension Reviews Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Current Drug Delivery Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment
Recent Patents on Anti-Cancer Drug Discovery Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews